Besponsa® (inotuzumab ozogamicin)
for Leukemia

Besponsa (inotuzumab ozogamicin) is a biological therapy used to treat CD22-positive B-cell acute lymphoblastic leukemia (ALL) in patients aged 1 year and older. It’s an antibody-drug conjugate combining an antibody targeting CD22—a protein on B-cell leukemia cells—with calicheamicin, a cytotoxic agent. Once inside cancer cells, calicheamicin damages DNA, causing cell death and reducing leukemia growth.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia